The recently published ALTITUDE study compared the effects of combination treatment of aliskiren on top of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) versus ACEI or ARB alone on cardiovascular and renal outcomes in 8561 patients with type 2 diabetes. 1 From a renal standpoint, this study was based on the pilot AVOID trial, where the addition of aliskiren on the background treatment of losartan significantly reduced proteinuria compared with placebo in patients with type 2 diabetes, hypertension and macroalbuminuria. 2 The premature termination of ALTITUDE at 69% of events due to renal complications, hyperkalaemia, and hypotension in the aliskiren group received a lot of attention and was considered as the end of the era of double renin-angiotensinaldosterone system (RAAS) blockade. The decision to terminate the trial early was justified statistically since event rate differences were unlikely to demonstrate a benefit of aliskiren if continued, and the authors provide a reasonable interpretation of results based on adverse events outweighing any anticipated benefits.
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However, there are some interesting points that one can raise from the full report of the study. Following the inclusion criteria (macroalbuminuria, or estimated glomerular filtration rate (eGFR) 30-60 ml/min/1.73m 2 and microalbuminuria, or eGFR 30-60 ml/min/1.73m 2 and history of cardiovascular disease), the mean age of the population was 65 years, 42% had cardiovascular disease, 67% had eGFR <45 ml/min/1.73m 2 , and only 58% of participants had macroalbuminuria. Included patients also had to have baseline blood pressure (BP) <135/85, or BP between 135/85 and 170/110 if treated with at least three antihypertensives; thus mean baseline BP was 137/74 mmHg and 69% of participants were receiving diuretics along with ACEI or ARB. 1 Therefore, a large proportion of patients could be susceptible to complications from BP lowering, much more from RAAS blockade. 3 In this population, no component of primary outcome differ between groups, with the exception of resuscitated cardiac arrest. Doubling of SCr was practically similar and the end-point of end-stage renal disease, dialysis or death due to kidney failure also did not differ between groups. In the aliskiren group, BP was lower by 1.3/0.6 mmHg, and albumin/creatinine ratio dropped by 14% more than placebo. Thus, the most interesting difference was the higher proportion of patients with hyperkalaemia (11.2% vs. 7.2%), and with reported hypotension (12.1% vs. 8.3%) in the aliskiren group. A higher frequency of hyperkalaemia with aliskiren was observed only in subjects with eGFR <60 ml/min/1.73m 2 ; in subgroup analyses the risk of the primary outcome was significantly higher only in patients with baseline potassium ≥6 mmol/l, a finding that could directly affect the overall outcome. Hypotension, on the other hand, was more frequent in the elderly and those receiving loop diuretics. 1 Aliskiren was selected on the theoretical advantage of preventing a rise in renin activity, resulting in more 'complete' RAAS blockade. 4 In this sense, the important side effects noted (i.e. hypotension, excessive eGFR drop and hyperkalaemia) can be directly attributed to 'potent' RAAS blockade in susceptible individuals, as also noted in ONTARGET study. 5 In essence, although ALTITUDE was carefully designed and suggests no benefit of dual RAAS blockade on cardiovascular and renal outcomes, its relevance for renoprotection may be limited by inclusion of people prone to hyperkalaemia and hypotension (i.e. a study population much different to the population of AVOID). Dual RAAS blockade may be of benefit in slowing chronic kidney disease progression in younger patients with proteinuria, eGFR >60 ml/min/1.73m 2 , and high compliance to dietary potassium restrictions. Previous trials including such patients found good tolerability and no hyperkalaemia with dual blockade. 2, 6 
